Table 3.
Comparison of treatment response assessments in imPERCIST and two other PET citeria (EORTC criteria and PERCIST).
| EORTC Criteria | PERCIST | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| PMD | SMD | PMR | CMR | Total | PMD | SMD | PMR | CMR | Total | |
| imPERCIST | ||||||||||
| PMD | 13 | 0 | 0 | 0 | 13 | 13 | 0 | 0 | 0 | 13 |
| SMD | 3 | 4 | 2 | 0 | 9 | 2 | 7 | 0 | 0 | 9 |
| PMR | 2 | 0 | 1 | 0 | 3 | 2 | 0 | 1 | 0 | 3 |
| CMR | 0 | 0 | 0 | 5 | 5 | 0 | 0 | 0 | 5 | 5 |
| Total | 18 | 4 | 3 | 5 | 30 | 17 | 7 | 1 | 5 | 30 |
Data are presented as numbers. Abbreviations: EORTC: European Organization for Research and Treatment of Cancer, PERCIST: Positron Emission Tomography Response Criteria in Solid Tumors, imPERCIST: immunotherapy-modified Positron Emission Tomography Response Criteria in Solid Tumors, PMD: progressive metabolic disease, SMD: stable metabolic disease, PMR: partial metabolic response, CMR: complete metabolic response.